WuXi AppTec IPO Valuation: Not Much Money Left on the Table
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
594 Views
WuXi AppTech IPO Update: Figuring Out the Right AH Premium
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
712 Views
U.S. Equity Strategy: Retest of October Lows Underway; Upgrading Financials
Our outlook remains cautious as we continue to expect heightened volatility and a potential retest of the February 2018 lows over the next several...
525 Views
Wuxi Apptec 药明康德 IPO: Welcome to the A/H Universe
WuXi Apptec is set to be the newest A/H pair with its upcoming HK listing that is set to raise USD 1 billion. The A-share (603289 CH) recorded 15...
833 Views
WuXi AppTech IPO Trading Update: What’s up with the Poor Cash Conversion?
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
893 Views